Holen Sie sich die Stockscreener-App
1.28
5.19%
-0.07
Vorhandelsmarkt:
1.30
0.02
+1.56%
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com
Geode Capital Management LLC Sells 31,279 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Recent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past year - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Russell Investments Group Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
FATE Shares Experience Decline in Value - knoxdaily.com
Analyzing Ratios: Fate Therapeutics Inc (FATE)’s Financial Story Unveiled - DWinneX
Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX
JPMorgan Chase & Co. Reduces Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Inc [FATE] Stock trading around $1.25 per share: What’s Next? - dbtnews.com
Nothing is Better Than Fate Therapeutics Inc (FATE) stock at the moment - Sete News
Is Fate Therapeutics Inc (NASDAQ:FATE) stock a better investment at this time? - uspostnews.com
Franklin Resources Inc. Has $273,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Vanguard Group Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag - MSN
Fate Therapeutics gets RMAT status from FDA for Lupus treatment - MSN
Fate Therapeutics’ iPSC-derived CAR-T FT819 Nabs FDA RMAT Designation for Lupus - CGTLive®
Fate Therapeutics’ new CAR T-cell therapy fast-tracked by FDA - Investing.com South Africa
Fate Therapeutics receives RMAT designation from FDA for FT819 - TipRanks
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic - MSN
Fate Therapeutics gets RMAT status from FDA for lupus treatment - Seeking Alpha
Fate Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy Designation for Lupus Cell Therapy; Shares Fall - marketscreener.com
Fate Therapeutics, Inc. Receives Regenerative Medicine Advanced Therapy Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus - marketscreener.com
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) - GlobeNewswire
American Century Companies Inc. Buys 12,295 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
NK Cells Market Hits New High | Major Giants NantKwest, Fate Therapeutics, Affimed, Glycostem, Nkarta - openPR.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Prudential Financial Inc. - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Position Decreased by Thrivent Financial for Lutherans - Defense World
Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? - MSN
Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average – Here’s What Happened - Defense World
Fate Therapeutics Inc [FATE] Former Officer and Director makes an insider purchase of 113,178 shares worth 0.1 million. – Knox Daily - knoxdaily.com
FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Fate Therap stock hits 52-week low at $0.87 amid sharp decline - Investing.com
FY2025 EPS Forecast for Fate Therapeutics Raised by Analyst - The AM Reporter
Equities Analysts Issue Forecasts for FATE FY2025 Earnings - Defense World
Weekly Research Analysts’ Ratings Updates for Fate Therapeutics (FATE) - Defense World
Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties - MSN
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Fate Therapeutics at Leerink Conference: Strategic Shift to FT-819 By Investing.com - Investing.com UK
Fate Therapeutics at Barclays Conference: Strategic Shift to Autoimmune Focus - Investing.com UK
FATE Stock Plummets to 52-Week Low at $0.87 Amidst Sharp Decline - Investing.com
Fate Therapeutics (NASDAQ:FATE) Rating Lowered to “Sell” at StockNews.com - Defense World
Fate Therapeutics price target lowered to $2.50 from $3 at BofA - TipRanks
Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush - Defense World
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):